Amarin Corp Plc (AMRN)

[MedResCollab]

Sam81,

On scripts, if you look at the sector numbers they have not climbed much at all. Almost all of the "growth" in Vascepa scripts have come from transitions out of OM3-EE (generic Lovaza) and to Vascepa. Our view is that script "growth" (again, it's more transition than growth) will begin to level out over Q3.

But scripts for Vascepa only relay a short-term metric, and guarantee or portend nothing long-term. Amarin needs approval of the efficacy supplement and a win in the courts in Jan/early Feb (most bench trials for ANDA cases resolve in a week or two) for anything to matter. Current scripts are "noise."